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Introduction
So-called ‘stress-related mucosal damage’ (SRMD) is the 
broad term used to describe the spectrum of pathology 
attributed to the acute, erosive, inﬂ ammatory insult to 
the upper gastrointestinal tract associated with critical 
illness [1]. SRMD represents a continuum from asymp to-
matic superﬁ cial lesions found incidentally during endo-
scopy, occult gastrointestinal bleeding causing anemia, 
overt gastrointestinal bleeding and clinically signiﬁ cant 
gastrointestinal bleeding.
Prevalence
Stress ulceration was ﬁ rst described in 1969 when focal 
lesions in the mucosa of the gastric fundus were reported 
during post-mortem examinations in 7 (out of 150) 
critically ill patients [2]. Endoscopic studies have since 
identiﬁ ed that between 74–100 % of critically ill patients 
have stress-related mucosal erosions and subepithelial 
hemorrhage within 24 hours of admission (Figure 1a) [3]. 
Th ese lesions are generally superﬁ cial and asymptomatic, 
but can extend into the submucosa and muscularis 
propria and erode larger vessels causing overt and clini-
cally signiﬁ cant bleeding (Figure 1b).
Th e prevalence of overt and clinically signiﬁ cant 
bleeding depends on how these conditions are deﬁ ned, 
with the deﬁ nitions by Cook and colleagues the most 
widely accepted [4]. Th ese authors deﬁ ned overt gastro-
intestinal bleeding as the presence of hematemesis, 
bloody gastrointestinal aspirate or melena, while clinically 
signiﬁ cant bleeding is the association of overt gastro-
intestinal bleeding and either hemodynamic compromise, 
or the requirement for blood transfusion, or surgery. It is 
important to emphasize that SRMD excludes variceal 
bleeding. However, bleeding per se is a clinical endpoint, 
and some studies may have incorrectly included bleeding 
attributable to varices, as well as that from the lower 
gastrointestinal tract, as part of the SRMD spectrum. 
Th is distinction is often not clear in the literature, 
particularly in observational studies of SRMD in which 
clinically signiﬁ cant bleeding is a primary outcome, 
which may led to investigators inappropriately including 
variceal, or non-SRMD bleeding. Th e importance of this 
distinction is highlighted in a prospective study by Cook 
and colleagues, which identiﬁ ed the cause of hemorrhage 
in 22 (of 33) patients with clinically signiﬁ cant gastro-
intestinal bleeding by the use of endoscopy or surgery [4]. 
In this study, stress ulceration was identiﬁ ed as the sole 
source of bleeding in 14 patients, with evidence of 
ulceration noted in 4 (of the remaining 8) patients in 
whom another bleeding site was identiﬁ ed, which 
included esophageal and gastric varices, vascular 
anomalies, and an anastomosis bleed [4]. Accordingly, 
variceal or non-SRMD pathologies, which will not be 
prevented by stress ulcer prophylactic therapies, are a 
frequent cause of overt and clinically signiﬁ cant bleeding. 
Th is distinction is often not identiﬁ ed in observational 
studies, whereas randomized controlled studies com-
paring diﬀ erent therapies for the prevention of SRMD 
have excluded patients with previous ulcer and variceal 
disease. For this reason, prevalence data from inter-
vention studies may not be comparable to that from 
observational studies.
Nevertheless, data from earlier studies suggested that 
overt gastrointestinal bleeding occurred frequently, and 
in some studies up to 25  % of critically ill patients 
developed overt gastrointestinal bleeding [5]. It is now 
accepted that the condition is far more infrequent, with 
the prevalence reported as between 0.6 and 4  % of 
patients [4], [6]. Th e variation in prevalence is due, at 
least in part, to the cohort of patients studied and their 
risk factors for developing SRMD and it has been 
estimated that episodes of clinically signiﬁ cant stress 
© 2010 BioMed Central Ltd
Stress ulceration: prevalence, pathology and 
association with adverse outcomes
Mark P Plummer1,2*, Annika Reintam Blaser3, Adam M Deane1,2
This article is one of ten reviews selected from the Annual Update in Intensive Care and Emergency Medicine 2014 and co-published as a series 
in Critical Care. Other articles in the series can be found online at http://ccforum.com/series/annualupdate2014. Further information about the 
Annual Update in Intensive Care and Emergency Medicine is available from http://www.springer.com/series/8901.
R E V I E W
*Correspondence: mark.philip.plummer@gmail.com
1Discipline of Acute Care Medicine, University of Adelaide, Adelaide, Australia
Full list of author information is available at the end of the article
Plummer et al. Critical Care 2014, 18:213 
http://ccforum.com/content/18/2/213
© 2014 Springer-Verlag Berlin Heidelberg and BioMed Central
ulcer bleeding in patients without risk factors is negligible 
(~  0.1  %) [4]. Th e infrequency of the diagnosis in more 
recent epidemiological studies probably reﬂ ects an 
improvement in the overall management of the critically 
ill patient, including a focus on early aggressive resus ci-
tation, attenuating mucosal hypoperfusion, and an aware-
ness of the importance of early enteral nutrition [7].
Importance
Clinically signiﬁ cant gastrointestinal bleeding, as the 
name suggests, indicates that bleeding is substantive and 
important. It has been estimated that up to half of all 
patients with clinically signiﬁ cant upper gastrointestinal 
bleeding die in the intensive care unit (ICU) and, in 
survivors, the length of ICU stay increases by approxi-
mately 8 days [8]. It is, therefore, intuitive that preventing 
episodes of clinically signiﬁ cant gastrointestinal bleeding 
will lead to better patient outcomes. However, inter-
ventional studies that have reduced the incidence of 
stress ulceration have had no eﬀ ect on either mortality or 
length of stay [6], [9]. Plausible explanations for this lack 
of eﬀ ect following intervention are that:
(i) a demonstrable proportion of clinically signiﬁ cant 
bleeding is not attributable to SRMD and will not 
respond to acid suppressive therapy;
(ii) previous studies were underpowered;
(iii) the interventions studied have adverse eﬀ ects that 
negate any beneﬁ t from a reduction in stress ulcera-
tion; and
(iv) the association between development of clinically 
signiﬁ cant bleeding and mortality may not be causal, 
and that clinically signiﬁ cant bleeding may just be 
heralding a poor outcome.
Mechanisms
Putative mechanisms underlying SRMD include reduced 
gastric blood ﬂ ow, mucosal ischemia and reperfusion 
injury, all of which occur frequently in the critically ill [9]. 
In a prospective observational study of 2,200 critically ill 
patients, mechanical ventilation > 48 hours and coagulo-
pathy were identiﬁ ed as substantial risk factors for 
clinically signiﬁ cant bleeding (odds ratios 15.6 and 4.3, 
respectively) [4]. Studies of smaller cohorts, which were 
performed over 30 years ago, also reported associations 
between clinically signiﬁ cant bleeding and hypotension, 
sepsis, hepatic failure, renal failure, burns and major 
trauma [10].
Prevention of stress ulceration
Although clinically signiﬁ cant bleeding occurs infre-
quently, the severity of the associated complications has 
encouraged preventative approaches. For example, the 
FAST HUG mnemonic reminds clinicians to consider the 
need for stress ulcer prophylaxis on a daily basis [11]. 
Moreover, the recent Surviving Sepsis Campaign guide-
lines recommend the use of stress ulcer prophylaxis in 
patients with severe sepsis who have a risk factor, one of 
which is need for mechanical ventilation > 48 hours [12]. 
Somewhat surprisingly, the recommendation to prescribe 
a stress ulcer prophylaxis drug was listed as a 1B 
recommendation – translating into a ‘strong’ recom men-
dation. Th is recommendation was endorsed despite the 
accompanying discussion acknowledging that there are 
no data to demonstrate a mortality beneﬁ t when pres-
cribing these drugs [12].
Several drugs/techniques have been described to 
reduce the incidence of SRMD, including sucralfate, 
Figure 1. Stress-related mucosal disease. a Gastric antral erosions; 
b Pyloric ulcer with adherent clot.
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histamine-2 receptor blockers (H2RBs) and proton pump 
inhibitors (PPIs). Sucralfate acts by adhering to epithelial 
cells forming a physical cytoprotective barrier at the ulcer 
site, thereby protecting the gastric mucosa from the 
eﬀ ects of acid and pepsin. Sucralfate is more eﬀ ective 
than placebo in reducing overt bleeding, but has been 
shown to be inferior to H2RBs to reduce clinically 
signiﬁ cant bleeding [13]. Furthermore, sucralfate can 
impair the absorption of enteral feeds and co-adminis-
tered oral medication [14], and there is a potential risk of 
bezoar formation (particularly in the setting of impaired 
gastric motility) when administering sucralfate to 
patients who are concurrently receiving enteral liquid 
nutrient [15]. Since intravenous H2RBs and PPIs are now 
widely available, sucralfate is rarely used as a ﬁ rst-line 
therapy.
H2RBs competitively inhibit histamine binding to its 
G-protein coupled receptor on the basolateral membrane 
of gastric parietal cells, which results in a reduction in 
acid production and an overall decrease in gastric 
secretions. H2RBs were used in early studies as ﬁ rst-line 
stress ulcer prophylaxis therapy, and were shown to 
signiﬁ cantly reduce the risk of clinically important 
bleeding when compared to placebo [13]. A limitation of 
H2RB administration is that tachyphylaxis can occur 
rapidly. In health, the anti-secretory eﬀ ect of continu-
ously infused intravenous ranitidine is dramatically 
reduced within the ﬁ rst day of administration [16]. With 
intragastric pH monitoring, studies in health have 
demonstrated that 70  % of patients have an intragastric 
pH  >  4 in the ﬁ rst 24  hours of ranitidine intravenous 
infusion which falls to 26 % on the third day of continuous 
infusion [16]. Although similar studies have not been 
performed in the critically ill, these data raise concerns 
about the eﬃ  cacy of H2RBs during longer term use in the 
critically ill [16].
PPIs inactivate the H+/K+ ATPase enzyme at the 
secretory surface of the parietal cell, inhibiting the 
secretion of H+ ions and thereby increasing the pH of the 
gastric contents. In contrast to H2RBs the use of PPIs is 
not associated with the development of tolerance, with 
100  % of healthy subjects maintaining an intragastric 
pH  >  4 after 72  hours of continuous infusion of ome-
prazole [16]. In a recent meta-analysis, Alhazzani and 
colleagues reported that PPIs were more eﬀ ective than 
H2RBs at reducing clinically important and overt upper 
gastrointestinal bleeding, without appearing to increase 
the risk of nosocomial pneumonia [6]. Th e Surviving 
Sepsis Campaign guidelines recommend the use of PPIs 
rather than H2RBs for stress ulcer prophylaxis citing level 
2C evidence [12]. Previous studies of SRMD prophylaxis 
in the critically ill with PPIs are summarized in Table 1 
[17]–[29]. Although these studies have been subject to 
meta-analyses by various groups [6], [9], with somewhat 
divergent results, even when these analyses have shown a 
reduction in clinically signiﬁ cant bleeding with PPI use, 
there has been no corresponding reduction in mortality.
Potential adverse eff ects associated with stress 
ulcer prophylaxis therapy
Controversy surrounds the relationship between the use 
of stress ulcer prophylaxis and the development of 
infectious complications, particularly infection-related 
ventilator-associated complications (IVAC) and Clostri-
dium diﬃ  cile infection. Gastric acid plays an important 
role in natural host defense, with an intragastric pH < 4 
being optimal for bactericidal action [30]. Accordingly, 
suppressing gastric acid production and raising the 
intragastric pH above this bactericidal threshold has the 
capacity to increase colonization of the stomach with 
pathogenic organisms.
Stress ulcer prophylaxis and infection-related ventilator-
associated complications
For the purpose of this review, the updated term 
‘infection-related ventilator-associated complication’ has 
been used in preference to the previous term ventilator-
associated pneumonia (VAP). In 2013, the Centers for 
Disease Control and Prevention proposed new deﬁ ni-
tions for patients receiving mechanical ventilation, 
including IVAC to improve objectivity and facilitate 
comparability [31]. Although prior studies investigating 
stress ulcer prophylaxis have exclusively used the term 
VAP to report data, with the inherent subjectivity 
associated with this diagnosis, we believe that using the 
recently proposed deﬁ nitions for IVAC in future studies 
will more accurately determine whether stress ulcer 
prophylaxis increases adverse events during mechanical 
ventilation. It should be recognized, however, that the 
previous studies all referred to VAP rather than IVAC.
A mechanism that has been proposed to contribute to 
IVAC is the contamination of the oropharyngeal area by 
reﬂ ux of gastric ﬂ uid, with subsequent aspiration of the 
oropharyngeal bacteria to the lower airways [32]. Because 
numerous organisms are unable to live in an acidic 
environment, the administration of drugs to increase 
gastric pH could facilitate gastric colonization with 
pathogenic organisms and predispose to respiratory 
infec tions [30]. In ambulant patients, use of PPIs has 
been associated with an increased risk of community-
acquired pneumonia (CAP) [33]. Laheij et al. reported a 
1.89 fold increase in the risk of CAP in those taking PPIs 
versus those who had stopped using PPIs [33], with a 
correlation between dose of PPI and risk of pneumonia 
[33].
In the critically ill, however, data relating intragastric 
pH and pulmonary infections are inconsistent. Some 
studies have reported a higher occurrence of IVAC in 
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patients who received drugs to increase gastric pH 
compared to those who received sucralfate [34], 
supporting the importance of gastric acidity and the role 
of the entero-pulmonary route. However, Heyland et al. 
reported that while the delivery of acidiﬁ ed enteral feeds 
(pH  3.5) preserved gastric acidity and dramatically 
reduced gastric bacterial growth and lowered the rate of 
Gram-negative bacterial growth in tracheal suction, there 
was no reduction in frequency of VAP [35]. In a meta-
analysis of data comparing H2RBs and placebo, which 
Table 1. A summary of trials of proton pump inhibitors for stress ulcer prophylaxis
Author (year) Population Intervention UGI bleeding Pneumonia
Powell et al. 
(1993) [17]
Post-CABG, surgical ICU. 
Age: 57; APACHE II: N/R
Omeprazole i.v. 80 mg × 1, then i.v. 40 mg/day (n = 10)
Omeprazole i.v. 80 mg × 1, then i.v. 40 mg/8 h (n = 10)







Risaliti and Uzzau 
(1993) [18]
Post-major surgery, surgical ICU. 
Age: 62; APACHE II: N/R
Omeprazole i.v. 40 mg, then PO 20 mg/day (n = 14)





Levy et al. 
(1997) [19]
Medical and surgical ICU. 
Age: 57; APACHE II: 19
Omeprazole NG 40 mg/day (n = 32)









Age: N/A; APACHE II: N/R
Omeprazole NG 40 mg × 2, then NG 20 mg/day (n = 60) 0 (0 %) 17 (28 %)
Phillips et al. 
(1998) [21]
General ICU. 
Age: N/A; APACHE II: N/R
Omeprazole NG 40 mg × 2, then NG 20 mg/day (n = 33)





Azvedo et al. 
(1999) [22]
General ICU. 
Age: 57; APACHE II: N/R
Omeprazole i.v. 40 mg/12 h (n = 38)
Ranitidine c.i.v. 150 mg/24 h (n = 38)







Kantorova et al. 
(2004) [23]
Surgical ICU. 
Age: 47; APACHE II: 18
Omeprazole i.v. 40 mg/day (n = 72)
Famotidine i.v. 40 mg/12 h (n = 71)
Sucralfate NG 1 mg/6 h (n = 69)









Pan and Li 
(2004) [24]
Critically ill patients with severe 
acute pancreatitis. 
Age: 48; APACHE II: 12
Rabeprazole PO 20 mg/day (n = 20)





Conrad et al. 
(2005) [25]
General ICU. 
Age: 55; APACHE II: 23
Omeprazole NG 40 mg × 2, then NG 40 mg/day (n = 178)





Hata et al. 
(2005) [26]
Cardiac ICU. 
Age: 65; APACHE II: N/R
Rabeprazole PO 10 mg/day (n = 70)
Ranitidine PO 300 mg/day (n = 70)







Kotlyanskaya et al. 
(2008) [27]
Medical ICU. 
Age: 72; APACHE II: 28
Lanzoprazole PO (n = 45), dose not given





Somberg et al. 
(2008) [28]
Mixed ICU. 
Age 42; APACHE II: 15
Pantoprazole i.v. 40 mg/day (n = 32)
Pantoprazole i.v. 40 mg/12 h (n = 38)
Pantoprazole i.v. 80 mg/day (n = 23)
Pantoprazole i.v. 80 mg/12 h (n = 39)
Pantoprazole i.v. 80 mg/8 h (n = 35)













Solouki and Kouchak 
(2009) [29]
General ICU. 
Age 50; APACHE II: N/R
Omeprazole NG 20 mg/12 h (n = 61)





* Study reported clinical signifi cance, age and APACHE data are presented as mean.
APACHE II: Acute Physiological and Chronic Health Evaluation II; CABG: coronary artery bypass graft; c.i.v.: continuous intravenous infusion; i.v.: intravenous; NG: 
nasogastric; N/R: not recorded, PO: per oral; UGI: upper gastrointestinal.
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did not adjust for enteral nutrition, Cook et al. reported a 
trend towards increased rates of pneumonia with the 
routine use of H2RBs [13].
Despite PPI prophylaxis being a key recommendation 
of the Surviving Sepsis Guidelines, there have been no 
large-scale prospective randomized trials that have 
compared PPIs and placebo to determine the eﬃ  cacy 
and/or adverse events associated with their use [12]. 
Nevertheless, the rate of IVAC associated with PPI use is 
likely to be at least similar to that observed with H2RBs 
[6]. Furthermore, if tolerance to H2RBs occurs, and 
increasing pH increases the risk of IVAC, it is plausible 
that VAP rates will be even greater in patients receiving 
PPIs. Regardless of whether H2RBs or PPIs are more 
harmful in creating the ideal environment to alter 
bacterial colonization of the stomach, this issue is likely 
to be particularly relevant for enterally fed patients, as 
enteral feeding per se may be a risk factor for IVAC [36].
Stress ulcer prophylaxis and Clostridium diffi  cile infection
Symptomatic infection with C. diﬃ  cile occurs relatively 
frequently in mechanically ventilated critically ill 
patients. Using data from over 65,000 patients in the 
United States who required prolonged ventilation, C. 
diﬃ  cile-associated diseases were present in >  5  % of 
patients [37]. Furthermore C. diﬃ  cile infections are im-
portant because infection leads to a substantial increase 
in hospital length of stay (6.1  days; 95  % conﬁ dence 
interval 4.9–7.4) [37].
Th ere is a plausible biological mechanism that acid-
suppression increases the risk of developing C. diﬃ  cile 
colonization, because host immunity is compromised by 
a higher pH environment in the stomach [38]. Obser-
vational studies have reported an association between 
iatrogenic acid suppression and C. diﬃ  cile-associated 
diseases [38]. In a prospective case-control study of 303 
patients admitted to a general medical ward, Yearsley et 
al. reported a two-fold increase in C. diﬃ  cile-associated 
diseases in patients receiving PPIs [39]. However, to the 
best of our knowledge, there are no epidemiological data 
detailing C. diﬃ  cile-associated diseases in critically ill 
patients receiving stress ulcer prophylaxis.
Complications associated with long-term use of drug therapies
Although complications associated with the acute use of 
H2RBs and PPIs are of more relevance to critically ill 
patients, it should be recognized that chronic use of PPIs 
has been associated with osteoporosis and fractures [40]. 
Adverse eﬀ ects associated with chronic use may be 
important, as a recent observational study reported that 
around a third of patients given PPIs for stress ulcer 
prophylaxis went home on the drug despite there being 
no indication on discharge from hospital for their 
continued use [41].
Enteral feeds and the role of stress ulcer 
prophylaxis
Th e majority of the studies on which current recom men-
dations are based were performed over 20  years ago. 
Over that time, there have been changes to the perceived 
importance of enteral nutrition, with intragastric feeds 
commenced sooner after admission [42]. Liquid nutrient 
buﬀ ers gastric acid, increases mucosal blood ﬂ ow and 
induces the secretion of cytoprotective prostaglandins 
and mucus [43]. It is uncertain what inﬂ uence the route 
of enteral feeding has on the eﬀ ect of liquid nutrient. 
Although it is intuitive that only liquid nutrient adminis-
tered into the stomach could have these potentially 
beneﬁ cial eﬀ ects, delivery directly into the small intestine 
may have other advantages that lead to favorable 
outcomes [42]. Furthermore, because of duodenal-gastric 
reﬂ ux of liquid [32] and increase in mesenteric blood 
ﬂ ow due to small intestinal delivery [44], postpyloric 
delivery may still prevent development of stress ulcera-
tion. Nevertheless the so-called ‘early’ administration of 
enteral nutrition into the stomach has been suggested to 
have contributed substantially to the diminishing 
frequency of stress ulcer-related bleeding that has been 
observed over the last 30  years [7]. In the critically ill, 
continuous enteral nutrition has been shown to be more 
eﬀ ective at increasing intragastric pH than H2RBs and 
PPIs [45] and, in rats, enteral nutrition provides better 
protection against stress ulceration than do intravenous 
H2RBs [46]. Studies in humans to evaluate the eﬀ ects of 
enteral nutrition on gastrointestinal bleeding reduction 
have primarily been performed in patients post-burn 
injury. Interpretation of these data are problematic 
because of inconsistencies around the deﬁ nitions of 
SRMD, clinically signiﬁ cant upper gastrointestinal bleed-
ing and enteral nutrition [47]. Marik et al. performed a 
meta-analysis to evaluate the eﬀ ects of H2RBs and 
placebo [9]. In the subgroup of patients who received 
enteral feeds, stress ulcer prophylaxis did not reduce the 
risk of bleeding but increased VAP rates and mortality 
[9]. However, as acknowledged by the authors, subgroup 
analysis within a systematic review should be interpreted 
with caution. For this reason we consider the Marik 
review hypothesis-generating and prospective studies to 
determine the inﬂ uence of enteral nutrition on SRMD 
and stress ulcer prophylaxis-associated IVAC are urgently 
required.
Cost of routine prophylaxis
Models of cost-eﬀ ectiveness of stress ulcer prophylaxis 
advocate that prophylactic therapy be limited to patients 
with established risk factors for clinically signiﬁ cant 
bleeding [48]. In comparison to routine prophylaxis for 
all critically ill patients, this strategy has been shown to 
decrease H2RB drug costs by 80  % without altering the 
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frequency of gastrointestinal bleeding [49]. To our 
knowledge, a cost analysis has not been performed with 
PPIs in the critically ill. Based on historical data, however, 
stress ulcer prophylaxis would need to be routinely 
administered to 900 hospitalized patients to prevent one 
episode of clinically signiﬁ cant bleeding [50]. Since 
clinically signiﬁ cant stress ulcer bleeding occurs infre-
quently in patients without risk factors, routine stress 
ulcer prophylaxis is unlikely to be cost-eﬀ ective and 
should probably be avoided in this subgroup, particularly 
given the potential for harm with PPI and H2RB use. As 
described [41], almost a third of patients have PPIs 
continued on hospital discharge, which in itself will lead 
to increases in costs to individual patients and commu-
nities, independent of any long-term health concerns.
Conclusions
Using current resuscitation and feeding practices, clinically 
signiﬁ cant gastrointestinal bleeding, as a consequence of 
SRMD, appears to occur infrequently. Nevertheless, 
should clinically signiﬁ cant bleeding occur, it is asso-
ciated with signiﬁ cant morbidity and at least a 4-fold 
increase in ICU mortality. Patients with respiratory 
failure requiring mechanical ventilation for >  48  hours 
and those with coagulopathy are at the highest risk of 
clinically signiﬁ cant bleeding. Based on these obser-
vations, current guidelines suggest that this group is most 
likely to beneﬁ t from prophylactic therapy. Th e superior 
eﬃ  cacy of PPIs has shaped recommendations that these 
agents be used as ﬁ rst-line therapy. However, the routine 
use of stress ulcer prophylaxis in all critically patients 
may be harmful and is unlikely to be cost-eﬀ ective. 
Controversy surrounds pharmacologically increasing 
gastric pH, but there is mechanistic plausibility that this 
may increase the rate of IVAC and C. diﬃ  cile infections – 
both of which are associated with substantial morbidity 
and increased costs – particularly in those ventilated for 
> 48 hours. In contrast to recent recommendations from 
the Surviving Sepsis Campaign, we contend that the issue 
of stress ulcer prophylaxis is not settled and further 
prospective randomized trials are required to guide 
decision-making.
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